XERS — Stock Film
STOCK FILMSCENE 1/11XERS · $8.72
Stock Expert AI presents
XERS
Xeris Biopharma Holdings, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Xeris Biopharma Holdings, Inc. A quick introduction.

On the stock market since 2018, it operates in the world of health and science. It has 435 employees. Now — the numbers.

on the stock market since 2018
435 employees
$1.5B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, less than $1 stays as net profit.

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
85%Products
Products 85%Keveyis 14%Product, Other 1%
85% of all revenue comes from a single line: Products.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

THE SALES TREND
Sales are growing, year after year.

Average growth of 56% a year over the last 4 years. Red columns mark years that ended in a loss.

$49.6M
2021
$110.2M
2022
$163.9M
2023
$203.1M
2024
$291.8M
2025
INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
80
very strong

Profit power and business quality lead the class.

FINANCIAL STRENGTH
63
average

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
62
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
88
very strong

Sales are growing strongly for its sector.

PRICE MOMENTUM
71
strong

Clearly above the class average — a step short of the very top.

No real weak spot in any of the five subjects — a balanced report card.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Trading below its recent peak.

The stock trades below its recent peak — about 12% off the top. A pullback, not a collapse.

1
THE BRIGHT SIDE · 1/3
Sales keep climbing

Over the last 3 years, sales grew about 38% a year on average.

2
THE BRIGHT SIDE · 2/3
Strong cash, light debt

There is $111.0M in the vault; even if every debt were paid off, $73.3M would remain.

3
THE BRIGHT SIDE · 3/3
Analysts’ target sits above today’s price

The average analyst price target is $12.0038% above today’s price.

1
THE RISKS · 1/3
A rich price tag

The company’s market value is 2680 times its annual profit. Even a small disappointment could hit the price hard.

2
THE RISKS · 2/3
Executives aren’t buying

No clear buy-side message is coming from the executive floor. Council score: 3/10.

3
THE RISKS · 3/3
Costs eat into the margin

Costs swallow the gains that sales growth brings in. Council score: 4/10.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, XERS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: XERS is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film